Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 BillionInvestors Business Daily • 02/05/24
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cashGlobeNewsWire • 02/05/24
It's shaping up to be a great quarter for Europe's biggest companies — no thanks to Europe.Market Watch • 02/05/24
Novartis Stock Slumps After Drugmaker's Earnings, Guidance Fall Short of ExpectationsInvestopedia • 01/31/24
Novartis (NVS) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 01/31/24
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readoutsGlobeNewsWire • 01/31/24
Novartis (NVS) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresZacks Investment Research • 01/26/24
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumorsGlobeNewsWire • 01/19/24
Novartis (NVS) Stock Slides as Market Rises: Facts to Know Before You TradeZacks Investment Research • 01/19/24
Novartis' (NVS) Strong Portfolio, Pipeline to Fuel Growth in 2024Zacks Investment Research • 01/18/24
These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record HighZacks Investment Research • 01/16/24
Novartis (NVS) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research • 01/13/24